RC
ACUR

RegentAtlantic Capital’s Acura Pharmaceuticals ACUR Stock Holding History

RegentAtlantic Capital’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-300
Closed -$675 – 1138
2014
Q4 		$675 Buy
+300
New +$830 ﹤0.01% 1196

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

RegentAtlantic Capital's ACUR Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Acura Pharmaceuticals (ACUR) in Q1 2015, closing a stake of 300 shares — an estimated $675 sold.

RegentAtlantic Capital first reported a position in ACUR in Q4 2014 and held it in 1 quarter. The position peaked at $675 in Q4 2014. 27 funds tracked by Wall St. Rank hold ACUR as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Acura Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 300 Acura Pharmaceuticals shares in Q1 2015, an estimated $675.
  • RegentAtlantic Capital first reported a position in Acura Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Acura Pharmaceuticals position peaked at $675 in Q4 2014.
  • 27 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.